opioids and compounds

Clinical Home Page Slider 2014

Clinical oversight for injured workers to prevent abuse



Ancillary Benefits Management for Workers’ Compensation


Mobile app for workers compensation

About Us

myMatrixx provides pharmacy and ancillary services for workers’ compensation programs. Our services control costs with proactive clinical oversight throughout the claims process. With one online tool also available in a mobile app, clients can manage claims with real time data and detailed reporting.

Learn more

The Latest


myMatrixx Chief Clinical Officer Phil Walls Honored as CompPharma’s 2015 Person of the Year

Posted by On December 22, 2015

TAMPA, FL, December 18, 2015 – Phil Walls, Chief Clinical Officer for myMatrixx, has been recognized as CompPharma’s Person of the Year for 2015. CompPharma is a consortium of workers’ compensation pharmacy benefit management (PBM) companies that provides a platform for developing cost-effective tools and services that benefit its PBM members.  myMatrixx, a Tampa-based pharmacy […]

myMatrixx President Artemis Emslie Named to 2015 “Women to Watch” List

Posted by On December 21, 2015

One of 25 Women Honored as Leaders in the Insurance Industry TAMPA, December 8, 2015 – myMatrixx, a Tampa-based pharmacy and ancillary medical benefit management company, announced that Artemis Emslie, President of myMatrixx, has been recognized by Business Insurance magazine as an honoree on their 2015 “Women to Watch” list. The annual list spotlights 25 […]


The Opioid Paradox: Prescription Opioid Use Declines as Heroin Use Increases

Posted by On August 29, 2016

By Phil Walls, RPh I am blogging from Maine today as I attend the Maine Comp Summit. My presentation on Sunday, August 28, 2016 was “Understand the Problem First: Why Does Heroin Abuse Matter to a Claims Professional?” The short answer to that question is because, among other things, the Centers for Disease Control now […]

DEA Rejects Proposal to Change Classification of Marijuana

Posted by On August 12, 2016

by Brian Williams, PharmD, Research Fellow Marijuana remains a Schedule I drug In a letter from Acting Administrator Chuck Rosenberg, the U.S. Drug Enforcement Administration (DEA) has rejected a proposal to change the federal classification of marijuana from a Schedule I to a Schedule II drug. By keeping it in Schedule I, the DEA is […]

Visit Blog


View All